Kyle Hoehn

Professor Kyle Hoehn is a faculty member at the University of New South Wales (UNSW), affiliated with the School of Biotechnology and Biomolecular Sciences. His research focuses on developing mitochondrial uncoupler drugs for metabolic disorders including obesity, diabetes, and ageing. He coordinates the course 'Current Trends in Biotechnology' (BABS2011) and leads a research lab developing therapeutic molecules.

Education includes:

• BA Chemistry & Biology, University of Northern Colorado (2000)
• MS Biochemistry, Colorado State University (2001)
• PhD Biochemistry, Colorado State University (2005)

Research interests center on mitochondrial uncouplers for metabolic disease treatment, nutrient metabolism (particularly acetyl-CoA carboxylase enzymes), obesity reversal mechanisms, and healthy ageing interventions. His work integrates biochemistry, pharmacology, and drug development to address metabolic dysfunctions.

Recent publications (2023-2025) demonstrate a strong focus on mitochondrial uncouplers (BAM15, SHD865), metabolic pathway modulators, and anticancer agents. Predominant themes include liver-selective therapies, combination treatments for fatty liver disease, glucose metabolism inhibitors, and mechanistic studies in preclinical models.

Research is supported by:

• 2 NHMRC Ideas grants (2022-2025)
• 1 NHMRC Development grant (2022-2024)
• 1 NIH-R01 grant (2021-2025)

He leads a laboratory focused on mitochondrial drug development, utilizing mouse models for obesity, diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). The team specializes in compound synthesis, metabolic phenotyping, and translational therapeutic strategies.